It was supposed to be filed by the end of Sept, in
Post# of 147727
You get what you get with Nader and the expanding ambition for leronlimab. There are definitely downsides but there's no denying that the potential upside has consistently increased and a big reason is his deep belief in the drug.
I've long wished that Nader would dial it back with the overpromising and oversharing but that's who he is. He's not going to change. His passion and drive has brought the company this far so you take the good with the bad. People talk about separating the science from the management but you can't do that with the way things are. Leronlimab and Nader are essentially one.